Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06568614 · ClinicalTrials.gov registry record · Phase 1
An Investigational Study of BG-89894 Tablets in Participants With Advanced Solid Tumors
A Phase 1 study of Advanced or Metastatic MTAP-deleted Solid Tumors, sponsored by BeOne Medicines.
- Recruiting
- Registry status
- Phase 1
- Development phase
- 140
- Enrollment target
- 20
- Study locations
NCT06568614 is a Phase 1 study of Advanced or Metastatic MTAP-deleted Solid Tumors that is actively recruiting participants, run by BeOne Medicines. The registered enrollment target is 140 participants. The trial reports 20 study locations across 18 states.
The verdict
NCT06568614, a Phase 1 study of Advanced or Metastatic MTAP-deleted Solid Tumors, is actively recruiting participants, sponsored by BeOne Medicines.
- RECRUITING
- Registry status
- Phase 1
- Development phase
- 140 participants
- Enrollment target
- 20
- Study locations
Study Summary
This study is being done to learn more about a new drug called BG-89894 (previously known as SYH2039). Researchers want to see if the drug is safe, how well people can tolerate it, how it moves through the body, and whether it shows any early signs of helping to treat cancer. The information gathered may help guide how future studies are designed. The entire study is expected to last about four years. People who join the study may receive treatment for around six months and will be followed for about 12 months after their treatment ends. The study plans to enroll participants over a three-year period.
Conditions Studied
Interventions
- DRUG BG-89894
Study Locations (20)
Beijing Municipality
- Cancer Hospital Chinese Academy of Medical Sciences - Beijing
- Beijing Cancer Hospital - Beijing
- Beijing Tsinghua Changgung Hospital - Beijing
Maryland
- Sidney Kimmel Comprehensive Cancer At Johns Hopkins - Baltimore
Missouri
- Washington University School of Medicine - St Louis
New York
- Columbia University Irving Medical Center - New York
Virginia
- Next Virginia - Fairfax
New South Wales
- Blacktown Cancer and Haematology Centre - Blacktown
South Australia
- Cancer Research South Australia - Adelaide
Victoria
- St Vincents Hospital - Fitzroy
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 140 participants |
| Start Date | 2024-10-12 |
| Est. Completion | 2028-12-30 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06568614
The ClinicalTrials.gov registry entry for NCT06568614 describes a study currently listed as recruiting, categorized as Phase 1. The registered enrollment target is 140 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is BeOne Medicines, which has 29 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Advanced or Metastatic MTAP-deleted Solid Tumors appearing as the primary indexed condition, and to 1 intervention - of which BG-89894 is the first listed.
NCT06568614 reports 20 study locations spanning 18 distinct geographic areas - top geographies include Beijing Municipality, Maryland, Missouri.
Frequently Asked Questions
What is clinical trial NCT06568614 about?
NCT06568614 is a clinical study titled "An Investigational Study of BG-89894 Tablets in Participants With Advanced Solid Tumors". This study is being done to learn more about a new drug called BG-89894 (previously known as SYH2039). Researchers want to see if the drug is safe, how well people can tolerate it, how it moves through the body, and whether it shows any early signs of helping to treat cancer. The information gathere...
What is the current status of trial NCT06568614?
This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 140 participants. The study started on 2024-10-12. Estimated completion is 2028-12-30.
What conditions does trial NCT06568614 study?
This clinical trial studies the following conditions: Advanced or Metastatic MTAP-deleted Solid Tumors.
What interventions are being tested in trial NCT06568614?
The interventions under investigation include: BG-89894 (DRUG).
Who is sponsoring clinical trial NCT06568614?
This trial is sponsored by BeOne Medicines, which has 29 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06568614 being conducted?
This trial has 20 study locations across Maryland, Missouri, New York, Virginia, New South Wales. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.